Form 4: OptimizeRx CBO Awarded Equity and Stock Options

OptimizeRx's Chief Business Officer, Andrew J. D'Silva, received a grant of 10,417 restricted stock units and 23,437 stock options.

Summary

• Andrew J. D'Silva, Chief Business Officer of OptimizeRx Corp (OPRX), was granted 10,417 shares of common stock in the form of restricted stock units (RSUs) on August 21, 2025.
• These restricted stock units will vest in three equal annual installments, with the first vesting occurring on August 21, 2026.
• Additionally, D'Silva was granted 23,437 stock options with an exercise price of $16.14 per share on August 21, 2025.
• The stock options will also vest in three equal annual installments, beginning on August 21, 2026, and will expire on August 21, 2030.
• Following these transactions, D'Silva beneficially owns 47,514 shares of common stock directly and 23,437 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates management retention and alignment of interests, though it is a routine compensation event and does not signal a significant change in company fundamentals.

Positives

• The equity and option grants align the Chief Business Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• This compensation structure is a common method for retaining key executive talent within the company.

Negatives

• The future vesting and exercise of these awards could lead to minor dilution for existing shareholders, though this is a standard aspect of executive compensation.

Future Outlook

The grants imply a continued commitment from the Chief Business Officer to OptimizeRx's long-term strategic objectives and performance.

Industry Context

This transaction represents a routine executive compensation event, common in the healthcare technology sector, designed to attract, retain, and motivate senior leadership by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• Equity and option grants are a standard component of executive compensation packages across the technology and healthcare industries, aligning executive incentives with long-term shareholder value creation.
• Companies such as Veeva Systems (VEEV) and Teladoc Health (TDOC) frequently utilize similar structures for their senior leadership to foster retention and performance.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon vesting/exercise, but increased alignment of management's interests with shareholder value.
• Employees: Reinforces the company's commitment to competitive executive compensation, potentially impacting morale and retention strategies for other key personnel.

Next Steps

• The restricted stock units and stock options will vest in three equal annual installments, beginning on August 21, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity and option grant to a key executive, which is a standard component of compensation designed for retention and alignment. It does not present new information that would fundamentally alter the investment thesis for OptimizeRx Corp, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

OptimizeRx, OPRX, Andrew J. D'Silva, Chief Business Officer, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, Form 4